Skip to main content

NCT00236431 - A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease

A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease


Primary Citation

Not Yet Available


Data Specification

Annotated CRF

Available upon data request approval

Product Info

Generic Name
Galantamine
Product Name
RAZADYNE®
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
1,063
% Female
N/A
% White
N/A
Product Class
Alzheimer's Disease - Cholinesterase Inhibitors
Sponsor Protocol Number
GAL-INT-18
Data Partner
Johnson & Johnson
Condition Studied
Alzheimer Disease
Mean/Median Age (Years)
N/A

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.